Literature DB >> 16329659

Parvovirus B19: a new emerging pathogenic agent of inflammatory cardiomyopathy.

C T Bock1.   

Abstract

The human parvovirus B19 (PVB19), an erythrovirus causing diverse clinical manifestations ranging from asymptomatic or mild to more severe outcomes such as hydrops fetalis, is the only currently known human pathogenic parvovirus. Recently, PVB19 has been identified as a causative agent of pediatric and adult inflammatory cardiac diseases. The first hints for a possible etiopathogenetic role of the PVB19 infection and the development of cardiac dysfunction were demonstrated by molecular biology methods such as in situ hybridization (ISH) and polymerase chain reaction (PCR). In this regard, PVB19-associated inflammatory cardiomyopathy is characterized by infection of endothelial cells of small intracardiac arterioles and venules, which may be associated with endothelial dysfunction, impairment of myocardial microcirculation, and penetration of inflammatory cells in the myocardium.

Entities:  

Mesh:

Year:  2006        PMID: 16329659     DOI: 10.1007/3-540-30822-9_6

Source DB:  PubMed          Journal:  Ernst Schering Res Found Workshop        ISSN: 0947-6075


  2 in total

1.  Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1.

Authors:  Adrian Lupescu; C-Thomas Bock; Philipp A Lang; Susanne Aberle; Heike Kaiser; Reinhard Kandolf; Florian Lang
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

2.  Real time PCR reconfirmed three novel clinical associations of parvovirus B19: Non-occlusive bowel gangrene, amegakaryocytic thrombocytopenia & myositis.

Authors:  Janak Kishore
Journal:  Indian J Med Res       Date:  2015-07       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.